8th RAS-Targeted Drug Development Summit

RAS-targeted drug development has entered a pivotal new phase. Once considered "undruggable," RAS is now one of oncology's most competitive and fast-moving therapeutic frontiers, with next-generation inhibitors, pan-RAS strategies, novel modalities, and complex combination approaches advancing in parallel. As programmes expand beyond G12C into G12D, G12V, G13D, and multi-variant targeting, the challenge has shifted from discovery to delivering durable clinical impact.

The 8th RAS-Targeted Drug Development Summit is the industry's only forum dedicated exclusively to translating RAS therapies from early discovery through clinical development. Bringing together leaders across biopharma, including Bristol Myers Squibb, Amgen, Revolution Medicines, Verastem, Incyte, Jacobio Pharmaceuticals and NCI the meeting focuses on overcoming resistance, improving therapeutic durability, and accelerating development timelines.

Join senior RAS-focused experts to gain actionable insights on next-generation targeting strategies, innovative modalities, smarter combination design, and precision patient stratification, equipping you to advance more effective RAS therapies for broader patient populations.

URLs:

Tickets: https://go.evvnt.com/3578535-2?pid=5248

Brochure: https://go.evvnt.com/3578535-3?pid=5248

Prices:

Drug Developer Pricing - Conference + Pre-Conference Focus Day: USD 4397.00,

Drug Developer Pricing - Conference Only: USD 3099.00,

Academic and Research Institutes Pricing - Conference + Pre-Conference Focus Day: USD 3797.00,

Academic and Research Institutes Pricing - Conference Only: USD 2699.00,

Solution and Service Providers Pricing - Conference + Pre-Conference Focus Day: USD 5297.00,

Solution and Service Providers Pricing - Conference Only: USD 3799.00

Speakers: Nagi Ayad, Professor, Georgetown University, Silvia Coma, Senior Director - Translational and Preclinical Research, Verastem, Pete DeMuth, Chief Scientific Officer, Elicio Therapeutics, Matthew R. Farren, Associate Director - Tumor Biology, Incyte, George Fromm, Chief Scientific Officer, Kayak Therapeutics, Hua Gong, Vice President - Translational Medicine, BridgeBio Oncology Therapeutics, Michael Hamilton, Scientist, Vividion Therapeutics, Federico Innocenti, Senior Director, Clinical Development, Solid Tumors, BeOne Medicines, Reagan Jarvis, Chief Executive Officer, Annoca, Jingjing Jiang, Vice President - Translational Research, Revolution Medicines, Jeff Kutok, Chief Scientific Officer, Ensem Therapeutics, Wonil Kim, Chief Scientific Officer, Aston Sci, Mani Mohindru, Chief Executive Officer, Cardiff Oncology, Geoff Oxnard, Chief Medical Officer, BlossomHill Therapeutics, Jonathan Pachter, Chief Scientific Officer, Verastem, Chad Pecot, Chief Scientific Officer, EnFuego Therapeutics, Craig Ramirez, Co-Founder and Chief Executive Officer, Tezcat Biosciences, Jeffrey Rothman, Chief Scientific Officer, Oncogenuity, Ivana Sullivan, Clinical Research Medical Director, Amgen, Andrew Stephen, Team Lead - Biochemistry and Biophysics Research Team, NCI, RAS Initiative, Thomas Spires, Senior Director - Translational Medicine, Bristol Myers Squibb, Mitchell Shirvan, Chief Scientific Officer, Silexion Therapeutics, Tony Tran, Director - Clinical Development, Kura Oncology, Andreas Varkaris, Assistant Professor in Medicine, Harvard Medical School, Andrea Wang-Gillam, Chief Medical Officer, Jacobio, Yizhe Wu, Head of Drug Discovery, HealZen Therapeutics, Lan Xu, Senior Vice President - Translational Medicine, Polymed Biopharmaceuticals, Zhan Yao, Executive Director - Discovery Signaling, Loxo Oncology at Lilly

• 
  Sponsored

  The Night Bazaar: Summer Season Finale

  Thursday, Aug 13, 2026 goes until 08/14

  The Charles River Speedway
• 
  Sponsored

  Juegos de Palabras: Spanish game night at BASE

  Wednesday, Aug 26, 2026 6:00p

  Boston Area Spanish Exchange (BASE)
• 
  Sponsored

  Amazing Commonwealth Avenue with the Elephants!

  Wednesday, Aug 12, 2026 2:00p

  Alexander Hamilton Statue

Sesh by The Boston Calendar | Advertise Terms | Privacy Policy | About